Urticaria and angioedema in renal cell cancer patients treated with IL-2.
Interleukin-2 therapy has produced significant improvement in a proportion of patients with renal cell cancer. Dermatologic side effects, such as erythema, have been very common. However, we could find only 2 reports of urticaria in the medical literature. Here, we report 8 patients with renal cell cancer who developed urticaria in association with interleukin-2 therapy. The hives tended to occur at the end of a treatment cycle. Skin tests with IL-2 were negative in two patients. Urticaria did not worsen or consistently occur with repeated courses of interleukin-2 and anaphylaxis was not observed in any patient. Six of the 8 patients previously had urticaria unrelated to IL-2 therapy.
Logan
Theodore F
TF
Indiana University School of Medicine, Division of Hematology/Oncology, Indianapolis, Indiana 46202, USA. tlogan@iupui.edu
Strippoli
Giovanni
G
Levine
Macy I
MI
D000368:Aged; D000799:Angioedema / Q000139:chemically induced*; D002292:Carcinoma, Renal Cell / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014581:Urticaria / Q000139:chemically induced*
D007376:Interleukin-2